Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Letters: Comments and Responses

α-Glucosidase Inhibitors for Patients With Type 2 Diabetes

Response to van de Laar et al.

  1. Markolf Hanefeld, MD, PHD1,
  2. Robert G. Josse, MBBS2 and
  3. Jean-Louis Chiasson, MD3
  1. 1Centre for Clinical Studies, Science and Technology Transfer\NTechnical University Dresden, Dresden, Germany
  2. 22Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Canada
  3. 33Centre Hospitalier de l’Ùniversite de Montreal-Hotel-Dieu and Department of Medicine, Montreal University, Montreal, Canada
  1. Address correspondence to Markolf Hanefeld, MD, PhD, Science and Technology Transfer\NGWT TU Dresden, Centre for Clinical Studies, Fiedler Str. 34, Dresden 01307, Germany. E-mail: hanefeld{at}gwtonline-zks.de
Diabetes Care 2005 Jul; 28(7): 1840-1840. https://doi.org/10.2337/diacare.28.7.1840
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Response to van de Laar et al.

The authors of the Cochrane systematic review carefully analyzed all available studies that fulfilled the criteria of randomized clinical trials of at least 12 weeks’ duration (1). With the exception of one study (2), all registered mortality and morbidity as secondary objectives. Glycemic control was the primary objective in 40 of 41 of these trials. Thus, the major legitimate conclusion of this careful analysis was that “AGIs [α-glucosidase inhibitors] have clear beneficial effects on glycemic control” mainly through their dose-dependent effect on postprandial hyperglycemia.

However, the authors also state as one of their main conclusions that they “found no evidence for an effect on mortality or morbidity.” Although this statement may be mathematically correct, it is misleading as it purports to be based on a solid analysis of the data from the 41 studies. This is not the case in their meta-analysis. Most of the selected trials had a treatment period of ≤24 weeks; many were of 3-month duration only and were therefore not designed and powered to investigate hard clinical end points such as morbidity or mortality. This is well reflected by the fact that, as reported by the authors, information on morbidity or mortality could only be retrieved in 3 of the 41 trials. While one study showed a significant treatment effect regarding cardiovascular events, the others presented only general statements without providing any detail. It is well known that sample sizes of individual clinical trials are often too small to detect clinically important effects reliably and that this is one of the reasons why meta-analysis is employed (3,4). However, hard end points such as cardiovascular mortality are going to be very rare in short-term duration studies unless compensated for by a huge population sample. Therefore, including short-term duration studies in their meta-analysis dilutes the cases of cardiovascular mortality. That biases the interpretation of the data analyzed.

The MERIA (MEta-analysis of Risk Improvement under Acarbose) analysis of seven placebo-controlled, long-term, randomized studies examining the effect of acarbose on cardiovascular-related mortality and morbidity showed a reduction of cardiovascular events in patients with type 2 diabetes (5). This analysis is based on all available acarbose studies with a minimum treatment duration of 52 weeks from a database including individual patient data. Because of this, publication and selection bias were already ruled out, as discussed in the response (6) to the criticism raised by van de Laar and Lucassen. Unfortunately, the same criticism voiced previously is repeated in their meta-analysis without taking the detailed response into consideration. In summary, the MERIA analysis showed a beneficial effect on cardiovascular complications in patients with established type 2 diabetes, a finding which is in accordance with the results from the STOP-NIDDM trial in subjects with impaired glucose tolerance (7).

We fully agree with the authors’ statement that prospective trials with the primary objective of investigating cardiovascular events and mortality are required to confirm the beneficial effect of acarbose on cardiovascular events in these high-risk populations. However, the combined data from the STOP-NIDDM trial and the MERIA meta-analysis are highly suggestive of the preventive effects of acarbose on cardiovascular complications in subjects with glucose intolerance.

Footnotes

  • DIABETES CARE

References

  1. ↵
    van de Laar FA, Lucassen PL, Akkermans RP, von de Lisdonk EH, Rutten GE, van Weel C: α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28: 154–163, 2005
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Holman RR, Cull CA, Turner RC: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22: 960–964, 1999 (erratum in Diabetes Care22:1922, 1999)
    OpenUrl
  3. ↵
    Thompson SG: Biostatistics in Clinical Trials. Redmond CK, Colton T, Eds. Chichester, NY, Wiley, 2001
  4. ↵
    Committee for Propietary Medicinal Products: Points to Consider on Application With 1: Meta-analyses, 2: One Pivotal Study. London, European Agency for the Evaluation of Medicinal Products, 2001
  5. ↵
    Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10–16, 2004
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Hanefeld MG: Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction scientifically credible: reply (Letter). Eur Heart J 25: 1179–1180, 2004
    OpenUrlFREE Full Text
  7. ↵
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494, 2003
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 28 (7)

In this Issue

July 2005, 28(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
Markolf Hanefeld, Robert G. Josse, Jean-Louis Chiasson
Diabetes Care Jul 2005, 28 (7) 1840; DOI: 10.2337/diacare.28.7.1840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

α-Glucosidase Inhibitors for Patients With Type 2 Diabetes
Markolf Hanefeld, Robert G. Josse, Jean-Louis Chiasson
Diabetes Care Jul 2005, 28 (7) 1840; DOI: 10.2337/diacare.28.7.1840
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension
  • Cigarette Smoking Is Associated With Low Glomerular Filtration Rate in Male Patients With Type 2 Diabetes
Show more Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.